DexCom, Inc. DXCM

NASDAQ · Healthcare · Medical - Devices

$79.32

Close on Fri, 20 Nov 2026 · market value $29.6B

What the price is betting on

In line with its record

At $79, the price assumes revenue grows about 15% a year for five years, from $5.1B to about $9.2B by FY2030. That is about one and a half times what analysts expect for the next two years and about the same as the company's own last three years.

The price assumes15%
Analysts, next two years11%
Last 3 years13%

Revenue growth a year. The price figure comes from a reverse DCF at a 10% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than DXCM? Check up to 5 of your stocks at once, free, no account.

0$2.5B$5B$7.5B$10B$5.1B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$51

Base

$66

Bull

$80

Today $79

  • Bear $51. Growth keeps slowing below the latest quarter's pace as competitors and reimbursement bite. Gross margin keeps eroding, as it has for four years with no sign of pricing power, so cash flow grows more slowly than sales and than analysts expect. A premium-priced stock then loses its premium.
  • Base $66. Sales keep growing near the latest quarter's pace, and gross margin stops falling from its current level. Operating leverage keeps cash flow tracking sales, so cash flow grows about as fast as analysts expect before fading to a long-run rate.
  • Bull $80. New uses for G7 and partnerships such as Beta Bionics and the Canadian pregnancy approval lift sales growth back toward last year's pace. Operating leverage, seen in the latest quarter's profit rise, keeps turning that growth into cash, and gross margin stops sliding, so cash flow grows faster than analysts expect.

AI-written stories, valued by code from the same model.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$5.3B$5.2B, on the path
  3. FY2027$6.1B$5.8B, below the path
  4. FY2028$7B$6.4B, below the path
  5. FY2029$8B$7.1B, below the path
  6. FY2030$9.2B$7.8B, below the path

Each year's revenue at 15% growth from $5.1B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Devices · listed on NASDAQ

Revenue, FY2025
$4.7B
Growth, 3 years a year
13%
Cash margin
23%
Net cash
$609M
Shares, 3-year change
−5.1%
Dividend yield
0%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.